Related Experiment Video
Updated: Oct 1, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on
Khaled Mahmoud1,2, Shady Swidan3,4, Mohamed El-Nabarawi5
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, 11837, Egypt.
Abstract:
Liver cancer is considered one of the deadliest diseases with one of the highest disease burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is considered to be the most common type. Multiple conventional approaches are being used in treating hepatocellular carcinoma. Focusing on drug treatment, regular agents in conventional forms fail to achieve the intended clinical outcomes. In order to improve the treatment outcomes, utilizing nanoparticles-specifically lipid based nanoparticles-are considered to be one of the most promising approaches being set in motion. Multiple forms of lipid based nanoparticles exist including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, phytosomes, lipid coated nanoparticles, and nanoassemblies. Multiple approaches are used to enhance the tumor uptake as well tumor specificity such as intratumoral injection, passive targeting, active targeting, and stimuli responsive nanoparticles. In this review, the effect of utilizing lipidic nanoparticles is being discussed as well as the different tumor uptake enhancement techniques used.
Insights
Lipid-based nanoparticles show promise for improving hepatocellular carcinoma treatment outcomes. This review explores various nanoparticle types and tumor targeting strategies to enhance drug delivery for liver cancer.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
- Conventional treatments for HCC often yield suboptimal clinical results.
- There is a critical need for advanced therapeutic strategies to improve HCC management.
Purpose of the Study:
- To review the application of lipid-based nanoparticles (LNPs) in hepatocellular carcinoma treatment.
- To discuss various LNP formulations and their potential benefits.
- To explore strategies for enhancing tumor uptake and specificity of LNP drug delivery.
Main Methods:
- Literature review of studies on lipid-based nanoparticles for liver cancer.
- Analysis of different LNP types: liposomes, solid lipid nanoparticles, nanostructured lipid carriers, etc.
- Examination of tumor targeting techniques: passive, active, and stimuli-responsive approaches.
Main Results:
- LNPs offer a promising platform for improving drug delivery in HCC.
- Various LNP formulations demonstrate potential for enhanced therapeutic efficacy.
- Targeting strategies can significantly improve nanoparticle accumulation within tumors.
Conclusions:
- Lipid-based nanoparticles represent a significant advancement in the treatment of hepatocellular carcinoma.
- Optimizing LNP design and employing targeted delivery systems are crucial for maximizing treatment effectiveness.
- Further research into LNP-based therapies holds great potential for managing liver cancer.
